Malignant Melanoma: Update Bulletin [Jan 2016]
Gain new KOL insights on the latest events happening in Malignant melanoma (MM): Opdivo’s (nivolumab; Bristol-Myers Squibb) label expansion to allow its use both as a monotherapy for the first-line treatment of BRAF V600 wild-type advanced melanoma, and in combination with Yervoy (ipilimumab; Bristol-Myers Squibb), also for treating BRAF V600 wild-type advanced melanoma; Yervoy’s (ipilimumab; Bristol-Myers Squibb) use as an adjunctive therapy for stage III melanoma; FDA’s approval of Keytruda (pembrolizumab; Merck & Co.) for the first-line treatment of advanced melanoma; Views on the role of Array BioPharma’s binimetinib as a therapy for NRAS-mutant melanoma, and the prospects for Amgen’s newly-approved oncolytic immunotherapy Imlygic (talimogene laherparepvec), are also summarised.
Key Questions Answered in this Update Bulletin:
Gain new KOL insights on the latest events happening in Malignant melanoma (MM): Opdivo’s (nivolumab; Bristol-Myers Squibb) label expansion to allow its use both as a monotherapy for the first-line treatment of BRAF V600 wild-type advanced melanoma, and in combination with Yervoy (ipilimumab; Bristol-Myers Squibb), also for treating BRAF V600 wild-type advanced melanoma; Yervoy’s (ipilimumab; Bristol-Myers Squibb) use as an adjunctive therapy for stage III melanoma; FDA’s approval of Keytruda (pembrolizumab; Merck & Co.) for the first-line treatment of advanced melanoma; Views on the role of Array BioPharma’s binimetinib as a therapy for NRAS-mutant melanoma, and the prospects for Amgen’s newly-approved oncolytic immunotherapy Imlygic (talimogene laherparepvec), are also summarised.
Key Questions Answered in this Update Bulletin:
Key Questions Answered in this Update Bulletin:
- Will Opdivo monotherapy use increase significantly following BRAF V600 wild-type label expansion?
- To what extent will Keytruda be used as a first-line therapy for advanced melanoma?
- Will Opdivo plus Yervoy’s superior efficacy be sufficient to secure a role for the combination in the BRAF V600 wild-type setting?
- What do KOLs think about Imlygic plus checkpoint inhibitors, to the future success of this oncolytic immunotherapy?
- How significantly will the need for patient monitoring impact Yervoy’s uptake in stage III melanoma?
- How successful do KOLs think that binimetinib will be for treating advanced NRAS-mutant melanoma?
Gain new KOL insights on the latest events happening in Malignant melanoma (MM): Opdivo’s (nivolumab; Bristol-Myers Squibb) label expansion to allow its use both as a monotherapy for the first-line treatment of BRAF V600 wild-type advanced melanoma, and in combination with Yervoy (ipilimumab; Bristol-Myers Squibb), also for treating BRAF V600 wild-type advanced melanoma; Yervoy’s (ipilimumab; Bristol-Myers Squibb) use as an adjunctive therapy for stage III melanoma; FDA’s approval of Keytruda (pembrolizumab; Merck & Co.) for the first-line treatment of advanced melanoma; Views on the role of Array BioPharma’s binimetinib as a therapy for NRAS-mutant melanoma, and the prospects for Amgen’s newly-approved oncolytic immunotherapy Imlygic (talimogene laherparepvec), are also summarised.
Key Questions Answered in this Update Bulletin:
- Will Opdivo monotherapy use increase significantly following BRAF V600 wild-type label expansion?
- To what extent will Keytruda be used as a first-line therapy for advanced melanoma?
- Will Opdivo plus Yervoy’s superior efficacy be sufficient to secure a role for the combination in the BRAF V600 wild-type setting?
- What do KOLs think about Imlygic plus checkpoint inhibitors, to the future success of this oncolytic immunotherapy?
- How significantly will the need for patient monitoring impact Yervoy’s uptake in stage III melanoma?
- How successful do KOLs think that binimetinib will be for treating advanced NRAS-mutant melanoma?
